Empaveli, Aspaveli(pegcetacoplan)
Aspaveli, Empaveli, Syfovre (pegcetacoplan) is a protein pharmaceutical. Pegcetacoplan was first approved as Empaveli on 2021-05-14. It has been approved in Europe to treat paroxysmal hemoglobinuria. It is known to target complement C3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Empaveli, Syfovre
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pegcetacoplan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMPAVELI | Apellis Pharmaceuticals | N-215014 RX | 2021-05-14 | 1 products, RLD, RS |
| SYFOVRE | Apellis Pharmaceuticals | N-217171 RX | 2023-02-17 | 1 products, RLD, RS |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PEGCETACOPLAN, EMPAVELI, APELLIS PHARMS | |||
| 2028-05-14 | ODE-351 | ||
| 2026-05-14 | NCE | ||
| 2026-02-08 | M-288 | ||
PEGCETACOPLAN, SYFOVRE, APELLIS PHARMS | |||
| 2026-05-14 | NCE | ||
| 2026-02-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Pegcetacoplan, Empaveli, Apellis Pharms | |||
| 11844841 | 2038-12-09 | DP | U-3172, U-3173, U-3174 |
| 11040107 | 2038-04-09 | DP | U-3172, U-3173, U-3174 |
| 10035822 | 2033-11-15 | DP | |
| 10875893 | 2033-11-15 | DP | U-3124, U-3540 |
| 11292815 | 2033-11-15 | DS, DP | U-3124, U-3354, U-3540 |
| 10125171 | 2033-08-02 | DP | |
| 11661441 | 2033-01-13 | DP | U-3124, U-3540 |
| 7888323 | 2027-12-04 | DP | |
| 7989589 | 2027-12-04 | DP | |
| 9169307 | 2027-11-18 | DP | U-3123, U-3541 |
| Pegcetacoplan, Syfovre, Apellis Pharms | |||
| 8168584 | 2027-04-07 | U-3540, U-3542 | |
| 9056076 | 2026-10-25 | U-3540 | |
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Thrombotic microangiopathies | D057049 | — | M31.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | — | — | — | 1 | 1 |
| Hemoglobinuria | D006456 | — | R82.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pegcetacoplan |
| INN | pegcetacoplan |
| Description | Pegcetacoplan, sold under the brand name Empaveli, among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria and geographic atrophy of the retina. Pegcetacoplan is a complement inhibitor.
|
| Classification | Protein |
| Drug class | complement ligand inhibitors; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2019171-69-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298211 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16694 |
| UNII ID | TO3JYR3BOU (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
C3
C3
Organism
Homo sapiens
Gene name
C3
Gene synonyms
CPAMD1
NCBI Gene ID
Protein name
complement C3
Protein synonyms
acylation-stimulating protein cleavage product, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, C3a anaphylatoxin, complement component 3, complement component C3a, complement component C3b, epididymis secretory sperm binding protein Li 62p, prepro-C3
Uniprot ID
Mouse ortholog
C3 (12266)
complement C3 (Q80XP1)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Syfovre – Apellis Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,147 documents
View more details
Safety
Black-box Warning
Black-box warning for: Empaveli
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,167 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use